Skip to main content
KYMR logo

Kymera Therapeutics, Inc. (KYMR) Stock: Price, Forecast & Analyst Target

Kymera Therapeutics, Inc. (KYMR) — MoonshotScore 26/100 (Weak band), calculated Nov 18, 2026. Price $115.31 (-3.42%), as of the Nov 20, 2026 trading session; market cap $9.84B. Expected results Feb 25, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 10.13× (cash as of Sep 30, 2026) · expected results Feb 25, 2027

$115.31 −$4.08 (-3.42%) Market Cap $9.84B

Kymera Therapeutics, Inc. · KYMR · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered): Kymera Therapeutics develops small-molecule drug candidates that direct the body’s protein disposal machinery toward disease-causing proteins across immunology and oncology. Its value depends less on current reported revenue than on whether the degradation platform produces convincing clinical evidence before sustained research spending consumes too much of its financial cushion.

Price as of Nov 20, 2026

Key Statistics

26 of 100

MoonshotScore v2 · Kymera Therapeutics (KYMR)

Weak
Business Quality Thin (24)
Financial Safety Fortress (81)
Valuation Full (42)
Growth Durability Fading (24)
Momentum Surging (93)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A strong balance sheet, but bottom-tier quality, stalling growth and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Fortress; Valuation: Full; Growth Durability: Fading; Momentum: Surging.

  • EPS beat 3 of the last 8 reports
  • Altman Z 41.17 · Piotroski F 4
  • ROE -27.3% · ROA -17.6% · current ratio 11.13

Holding back: weak fundamentals, soft growth

Helping: balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for KYMR (58 recorded, newest six shown)
RecordedScoreBand
26Weak
26Weak
26Weak
26Weak
26Weak
26Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$115.31
Change on the day-3.42%
52-week range$62.91–$142.92
Market capitalisation$9.84B—
Shares traded on the day1.25M
Beta (volatility vs the S&P 500)2.03

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $59, high $132, latest $115. 4 reported quarters marked, 2 above and 2 below the recorded estimate. $132 $59 high $132 Feb 26, 2026 · Earnings results · reported below the recorded estimate · close $911Apr 30, 2026 · Earnings results · reported above the recorded estimate · close $812Aug 5, 2026 · Earnings results · reported above the recorded estimate · close $1083Oct 29, 2026 · Earnings results · reported below the recorded estimate · close $1274 Oct 17, 2025 Nov 20, 2026 · $115 $60Oct 17, 2025$62Oct 31, 2025$65Nov 14, 2025$68Nov 28, 2025$90Dec 12, 2025$81Dec 26, 2025$75Jan 9, 2026$70Jan 23, 2026$80Feb 6, 2026$87Feb 20, 2026$83Mar 6, 2026$78Mar 20, 2026$85Apr 2, 2026$88Apr 17, 2026$81May 1, 2026$82May 15, 2026$81May 29, 2026$86Jun 12, 2026$108Jun 26, 2026$119Jul 10, 2026$111Jul 24, 2026$108Aug 7, 2026$120Aug 21, 2026$117Sep 4, 2026$118Sep 18, 2026$107Oct 2, 2026$105Oct 16, 2026$127Oct 30, 2026$128Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · below the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Kymera Therapeutics (KYMR): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Strong
Valuation Neutral
Growth Durability Weak
Momentum Strong

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Strong
ROE Negative
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Kymera Therapeutics (KYMR), and what does it report?

Short answer · as of

Kymera is a clinical-stage drug developer, not a medicine-volume business. Its candidates are designed to remove pathogenic proteins rather than merely inhibit them, with programs spanning inflammatory disorders, blood cancers, solid tumors, autoimmune disease and fibrosis.

Reported revenue therefore should not be read as patient demand. The financial statements currently measure development economics: volatile revenue alongside heavy research spending, recurring operating losses and no corresponding commercial sales trend.

2 · Latest results

What do the latest results show for Kymera Therapeutics (KYMR)?

The latest reported period brought a sharp revenue increase, a narrower operating loss and a less negative per-share result even as research spending climbed. Operating cash outflow also improved from the preceding period, though it remained substantial.

Recent reports reversed the earlier pattern of shortfalls by exceeding revenue and loss expectations. Because the pipeline remains in development, that improvement is better understood as a change in reported development economics than as evidence of rising medicine demand.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$0.00 Sep 30, 2026
Latest quarter · R&D
$128.51M Sep 30, 2026
Latest quarter · SG&A
$18.72M Sep 30, 2026
Latest quarter · FMP standardized operating result
−$147.23M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$0.00$128.51M$18.72M−$147.23M
Jun 30, 2026$65.00M$119.48M$21.13M−$75.61M
Mar 31, 2026$34.37M$98.16M$20.36M−$84.15M
Dec 31, 2025$2.86M$83.86M$16.95M−$97.90M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$1.35M Oct 29, 2026
Latest report · revenue estimate
$3.28M Oct 29, 2026
Latest report · revenue vs estimate
Below estimate Oct 29, 2026
Latest report · EPS vs estimate
Below estimate Oct 29, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 29, 2026$1.35M$3.28M−$1.3200−$1.2600
Aug 5, 2026$65.00M$32.78M−$0.6200−$0.7126
Apr 30, 2026$34.37M$8.27M−$0.7100−$0.8900
Feb 26, 2026$2.87M$15.05M−$0.9700−$0.7837
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2026$0-$132M-$1.32 (diluted)
Q2 FY2026$65M-$61M-$0.62 (diluted)
Q1 FY2026$34M-$69M-$0.71 (diluted)
Q4 FY2025$3M-$87M-$0.98 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Kymera Therapeutics (KYMR)?

Short answer

Cash and short-term investments were $971.21M at the Sep 30, 2026 balance-sheet date. Operating cash flow was −$77.91M for the quarter ended Sep 30, 2026, meaning operations used cash. These figures do not establish a cash runway.

Cash and investments dwarf debt, total liabilities and recent operating cash outflows. Liquidity ratios and the distress screen reinforce that near-term solvency is not the immediate constraint, although much of the broader resource total sits in long-term investments rather than cash and short-term holdings.

The vulnerability is persistent consumption of capital while research spending rises. Expected losses remain deep, and market value stands far above net cash, so clinical disappointment could remove anticipated pipeline value while leaving the expense base and cash burn intact.

Data-derived red flags

  • Negative return on equity (-27.3%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
−$77.91M Sep 30, 2026
Previous quarter · operating cash flow
−$54.06M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026−$77.91M−$310,000
Jun 30, 2026−$54.06M−$470,000
Mar 31, 2026−$88.84M−$430,000
Dec 31, 2025−$66.75M−$110,000
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Kymera Therapeutics (KYMR)?

Short answer · as of

The next earnings report is expected on Feb 25, 2027.

The next earnings release will test whether reported revenue falls back after its recent surge and whether the loss deepens as consensus expects. More durable observations are the direction of research spending, operating cash outflow and the split between readily available liquidity and longer-term investments.

Clinical progress across Kymera’s immunology and oncology programs matters more than quarterly revenue noise because the valuation assigns substantial worth beyond net cash. Recent disclosed insider activity consisted of sales and other transactions, with no purchases, making subsequent filings worth monitoring as a secondary signal rather than evidence about trial outcomes.

5 · Peer comparison

How does Kymera Therapeutics compare with its peers?

Short answer

Kymera Therapeutics's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Kymera differs from commercial biotechnology companies because its current revenue does not represent prescription volume; the economic asset is a protein-degradation platform and the clinical portfolio built from it. The same mechanism is being applied across inflammatory disease and cancer, giving the company broader biological exposure than a developer centered on a narrowly defined indication.

Compared with cash-burning drug developers, Kymera combines substantial investment resources with light debt. That financial flexibility supports development, but the valuation still depends predominantly on future clinical and strategic value rather than present revenue or cash generation.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Kiniksa Pharmaceuticals, Ltd. (KNSA) Same industry, near in market value$93.53 Nov 19, 2026$7.35B98 5-pillar Nov 18, 2026
Exelixis, Inc. (EXEL) Same industry, near in market value$64.63 Nov 20, 2026$15.8B98 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$315.82 Nov 19, 2026$9.36B96 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$91.35 Nov 20, 2026$10.4B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.67 Nov 20, 2026$11.4B92 5-pillar Nov 18, 2026
Corcept Therapeutics Incorporated (CORT) Same industry, near in market value$64.98 Nov 19, 2026$7.11B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$64.88 Nov 19, 2026$9.81B90 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Same industry, near in market value$124.02 Nov 19, 2026$8.09B88 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$97.57 Nov 19, 2026$6.62B67 5-pillar Nov 18, 2026
Belite Bio, Inc. (BLTE) Same industry, near in market value$151.02 Nov 19, 2026$6.13B64 5-pillar Nov 18, 2026
Praxis Precision Medicines, Inc. (PRAX) Named competitor$310.90 Nov 19, 2026$8.69B60 5-pillar Nov 18, 2026
Kymera Therapeutics (KYMR) — this page$115.31$9.84B26
Immunovant, Inc. (IMVT) Named competitor$32.52 Nov 19, 2026$6.73B25 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$115.00 – $180.00
Consensus target
$141.53
Median target
$140.00

Consensus record · Captured .

Measured against a quoted price of $115.31 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 1, 2026

Transactions
99
Identified insiders
7
Purchases
0
Sales
88
Other transactions
11

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Reporting holders
316 Period end Sep 30, 2026
Previous quarter · holders
295 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Fmr LLC12,568,921
Price T Rowe Associates INC /Md/8,725,908
Baker Bros. Advisors LP8,657,242
Avoro Capital Advisors LLC7,474,747
Blackrock, INC.5,825,416

Tracked investors

Which of the 16 named investors we follow held KYMR in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported KYMR in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Kymera Therapeutics (KYMR)?

Read these with our analysis →

What Investors Ask About Kymera Therapeutics (KYMR) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

What does Kymera’s targeted protein degradation platform do?

It uses small molecules to recruit the body’s inherent protein disposal system and selectively eliminate proteins associated with disease. Kymera applies that mechanism across inflammatory disorders, cancer, autoimmune disease and fibrosis.

How does IRAKIMiD fit Kymera’s oncology pipeline?

IRAKIMiD is designed for diffuse large B cell lymphoma carrying a particular mutation. It sits alongside other Kymera programs aimed at blood cancers and solid tumors.

Why can Kymera revenue rise while its medicines remain in development?

Kymera’s pipeline remains in clinical development, so reported revenue is not a measure of prescription demand. The latest increase improved reported losses, but research spending and operating cash outflow remained substantial.

Why are immunology and oncology linked inside Kymera’s pipeline?

Kymera is applying the same underlying protein-removal approach to different disease-causing targets. That creates a shared platform across inflammatory conditions, blood cancers, solid tumors, autoimmune disease and fibrosis, while each program retains its own clinical risk.

What is the KYMR stock price today?

The last price recorded for Kymera Therapeutics, Inc. (KYMR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the KYMR price target?

The analyst consensus price target for Kymera Therapeutics, Inc. (KYMR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 75 figures on this page — 1 from SEC filings and earnings calls, 66 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Legal name; Business description; Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Cash and investment components
  • 1. What is Kymera Therapeutics (KYMR), and what does it report?: Business description; Sector / industry (provider taxonomy); Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Kymera Therapeutics (KYMR)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Annual revenue and net result (USD millions); Business description
  • 3. What are the financial strengths and risks for Kymera Therapeutics (KYMR)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Distress and quality screens; Cash against market value; Analyst revenue and earnings estimates (average)
  • 4. What should you watch next at Kymera Therapeutics (KYMR)?: Next earnings report; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and investment components; Cash against market value; Business description; Insider transactions, last 180 days
  • 5. How does Kymera Therapeutics compare with its peers?: Business description; Cash, investments and debt; Cash and investment components; Operating cash flow by quarter (USD millions); Cash against market value; Trailing twelve-month ratio set
  • FAQ: What does Kymera’s targeted protein degradation platform do?: Business description
  • FAQ: How does IRAKIMiD fit Kymera’s oncology pipeline?: Business description
  • FAQ: Why can Kymera revenue rise while its medicines remain in development?: Business description; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters
  • FAQ: Why are immunology and oncology linked inside Kymera’s pipeline?: Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.